X
All Data
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Lead Product(s): Nafamostat
Therapeutic Area: Infections and Infectious Diseases Product Name: DS-2319
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
DS-2319 contains nafamostat mesilate that has been formulated in an inhalation dosage form. It is being studied for treating COVID-19 since it has been shown to block membrane fusion between the viral envelope that causes COVID-19 and the host plasma cell membrane.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
